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Gambling is characterized by cognitive distortions in the processing of chance and skill
that are exacerbated in pathological gambling. Opioid and dopamine dysregulation is
implicated in pathological gambling, but it is unclear whether these neurotransmitters
modulate gambling distortions. The objective of the current study was to assess the
effects of the opioid receptor antagonist naltrexone and the dopamine D2 receptor
antagonist haloperidol on gambling behavior. Male recreational gamblers (n = 62) were
assigned to receive single oral doses of naltrexone 50mg, haloperidol 2mg or placebo,
in a parallel-groups design. At 2.5 h post-dosing, participants completed a slot machine
task to elicit monetary wins, “near-misses,” and a manipulation of personal choice, and
a roulette game to elicit two biases in sequential processing, the gambler’s fallacy and
the hot hand belief. Psychophysiological responses (electrodermal activity and heart rate)
were taken during the slot machine task, and plasma prolactin increase was assessed.
The tasks successfully induced the gambling effects of interest. Some of these effects
differed across treatment groups, although the direction of effect was not in line with
our predictions. Differences were driven by the naltrexone group, which displayed a
greater physiological response to wins, and marginally higher confidence ratings on
winning streaks. Prolactin levels increased in the naltrexone group, but did not differ
between haloperidol and placebo, implying that naltrexone but not haloperidol may
have been functionally active at these doses. Our results support opioid modulation of
cognition during gambling-like tasks, but did not support the more specific hypothesis that
naltrexone may act to ameliorate cognitive distortions.
Keywords: naltrexone, haloperidol, pathological gambling, addiction, reward, motivation, decision-making,
psychophysiology
INTRODUCTION
Gambling is a widespread form of recreational risk-taking that
becomes excessive and pathological in a subset of the popula-
tion (around 1%; Wardle et al., 2010). Pathological gambling
is increasingly viewed as a “behavioral addiction” and has been
reclassified within the Addictions category in the DSM-5 (Petry
et al., 2013). Recent work on pathological gambling has studied
its underlying neurobiological basis, highlighting the similarities
with substance use disorders (Potenza, 2008) and focusing on
the neuroimaging of reward-based tasks (Limbrick-Oldfield et al.,
2013) and changes in neurotransmitter function (Leeman and
Potenza, 2012). A distinct cognitive approach to gambling has
emphasized the role of erroneous thinking styles (“cognitive dis-
tortions”) during gambling (Ladouceur and Walker, 1996; Clark,
2010): gamblers experience a variety of biases and erroneous
thoughts during play, pertaining in particular to their perceived
level of skill in controlling the outcomes (“the illusion of control”;
Langer, 1975) and their tendency to detect patterns in ran-
dom sequences (“the Gambler’s Fallacy”; Oskarsson et al., 2009).
While the gambling cognitions are apparent in non-problem
gamblers and student populations, the overall level of distorted
thinking is elevated in people with gambling problems (Miller
and Currie, 2008; Emond and Marmurek, 2010; Michalczuk
et al., 2011) and these cognitions can be targeted effectively by
cognitive-behavioral therapies (Fortune and Goodie, 2012). The
neurobiological mechanisms that underlie these gambling-related
distortions have received minimal attention to date, and the aim
of the present study was to examine their pharmacological basis,
looking at dopamine and opioid receptor manipulations, in a
sample of mild recreational gamblers.
The opioid system is the target of growing interest in patho-
logical gambling, primarily on the basis of clinical trials showing
significant benefits of the opioid receptor antagonists naltrexone
and nalmefene on gambling symptom severity and self-reported
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craving (Kim et al., 2001; Grant et al., 2006, 2008). These medica-
tions are well established in the clinical management of opiate and
alcohol dependence (O’Brien, 2005). Preclinical evidence indi-
cates that opioid receptors are distributed widely in the mesolim-
bic system, and can modulate dopamine transmission (Spanagel
et al., 1992). Endogenous opioids are implicated particularly in
hedonic aspects of reward processing (Pecina et al., 2006; Barbano
and Cador, 2007). Of relevance to gambling behavior, a phar-
macological fMRI study of the μ-opioid antagonist naloxone
found attenuated reward-related responses in the ventral stria-
tum, and enhanced loss-related activity in the medial prefrontal
cortex, on a wheel of fortune task in healthy volunteers (Petrovic
et al., 2008). Thus, the treatment effect in pathological gambling
may be mediated by a dual action of enhancing aversive process-
ing and attenuating positive processing of gambling outcomes.
The present study employed the opioid receptor antagonist nal-
trexone, which is a competitive antagonist at μ- and κ-opioid
receptors, and to a lesser extent at δ-opioid receptors (Kreek,
1996). We used a 50mg single dose that is widely used in other
cognitive studies in healthy volunteers (Katzen-Perez et al., 2001;
Mitchell et al., 2007; Boettiger et al., 2009).
Dopamine dysregulation has also been indicated in prob-
lem gambling, based on genetic data (Lobo and Kennedy, 2009)
and studies measuring peripheral markers (Bergh et al., 1997;
Meyer et al., 2004), as well as the provocative syndrome in
Parkinson’s Disease where medications acting at the dopamine
D2/D3-receptor are linked to the emergence of disordered gam-
bling as a side-effect (Voon et al., 2009; Djamshidian et al.,
2011). Dynamic PET studies with the dopamine D2/D3 radio-
tracer [11C]raclopride have confirmed that monetary reinforce-
ment induces dopamine release in healthy volunteers performing
gambling-like tasks (Zald et al., 2004; Martin-Soelch et al., 2011),
and the magnitude of dopamine release is elevated in at least
a subset of patients with pathological gambling (Steeves et al.,
2009; Linnet et al., 2011; Joutsa et al., 2012). In addition, acute
administration of the dopamine stimulant amphetamine, and
the D2-receptor antagonist haloperidol, were both seen to mod-
ulate gambling tendencies in pathological gamblers (Zack and
Poulos, 2004, 2007). In the present study, we sought to manip-
ulate dopamine transmission with haloperidol, a first genera-
tion antipsychotic with high D2 binding affinity in the striatum
(Kapur et al., 1996; Xiberas et al., 2001). We selected a low (2mg)
dose of haloperidol that we expected to act preferentially on the
presynaptic D2 auto-receptors to increase dopamine transmission
(Frank and O’Reilly, 2006).
We examined a number of gambling variables that can be
elicited with laboratory tasks. We used a slot machine task that
delivered unpredictable monetary wins as well as “near-miss”
outcomes: non-wins that are spatially proximal to a jackpot
win (Reid, 1986). Relative to “full-misses,” near-misses are rated
as unpleasant but increase motivations to continue gambling,
despite their objective non-win status (see also Kassinove and
Schare, 2001). Previous neuroimaging of this task showed that
near-misses recruited overlapping brain circuitry to the win out-
comes, including the ventral striatum and insula, in both healthy
volunteers and regular gamblers (Clark et al., 2009; Chase and
Clark, 2010). In the present study, we measured the subjective
response to these wins and near-misses with trial-by-trial ratings.
We also recorded psychophysiological activity following these
outcomes using electrodermal activity (EDA) and heart rate (HR)
recording, which have established sensitivity to gambling out-
comes (Dixon et al., 2011; Lole et al., 2012; Studer and Clark,
2011; Clark et al., 2012a). In addition, the slot machine task
measures one example of illusory control, the effect of personal
choice, by comparing the expectancies of winning under con-
ditions where the participant either chose, or was not able to
choose, the “play icon.” Subjects rate their expectancy of winning
as higher on participant-chosen trials (Clark et al., 2009, 2012a),
and fMRI signals to monetary wins are enhanced under this
choice manipulation (Coricelli et al., 2005; Studer et al., 2012).
We also administered a second task, based upon roulette,
which involved binary predictions of red or black outcomes and
a subsequent confidence rating (Ayton and Fischer, 2004). The
Gambler’s Fallacy is observed as the reduced choice of one color
(e.g., red) after a “run” of consecutive outcomes of that color
(e.g., four successive reds). In addition, participant’s confidence
ratings are sensitive to their prediction accuracy, with “streaks”
of consecutive correct guesses (i.e., wins) increasing self-reported
confidence, and incorrect predictions (i.e., a losing streak) leading
to decreased confidence. These are known as “hot hand” effects
(Gilovich et al., 1985; Ayton and Fischer, 2004). Past neuroimag-
ing studies found modulation of caudate, insula and medial
prefrontal cortex activity by streaks of wins and losses in binary
choice games (Elliott et al., 2000; Akitsuki et al., 2003).
As a preliminary investigation, we examined the effects of
haloperidol and naltrexone on these gambling variables in a
group of healthymale volunteers, who reported recreational gam-
bling involvement. There is evidence that both gambling-related
cognitive distortions, and problem gambling symptom severity,
exist on a continuum, such that recreational gamblers are con-
sidered at some degree of risk for later problematic gambling
(Toce-Gerstein et al., 2003; Raylu and Oei, 2004). Rates of gam-
bling involvement and the prevalence of pathological gambling
are typically higher in males (Bland et al., 1993; Shaffer et al.,
1999).
The overarching hypothesis was that the gambling cogni-
tions under scrutiny would be modulated by the dopamine
and opioid-based treatments. Given preclinical evidence that μ-
opioid blockade exerts a downstream effect on dopamine trans-
mission (Spanagel et al., 1992), we were further interested in the
overlap between the cognitive variables affected by naltrexone
and haloperidol. Previous work afforded a number of more spe-
cific predictions. First, there are some indications that dopamine
may modulate near-miss effects and illusory control, specifi-
cally. Using a rodent version of a slot machine, amphetamine
and the dopamine D2 agonist quinpirole increased erroneous
lever presses on a game with near-misses (2 of 3 identical sym-
bols) (Winstanley et al., 2011). Dopamine is also implicated
in perceptions of control (Declerck et al., 2006; Redgrave and
Gurney, 2006); for example, levodopa increased the sense of
agency (“action-effect binding”) on a timing task in patients with
Parkinson’s Disease (Moore et al., 2010). As such, we predicted
that the low dose of haloperidol would potentiate subjective
and physiological responses to win and near-miss outcomes, and
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enhance the influence of personal choice, on the slot machine
task. Second, drawing on Petrovic et al. (2008), we predicted
that the naltrexone group would show attenuated responses to
winning outcomes, coupled with enhanced negative processing
(affect following near-misses) on the two tasks. Given the lack
of past work to guide predictions about neurotransmitter effects
on the Roulette task, these data were analyzed in an exploratory
manner.
METHODS
PARTICIPANTS
Male participants (n = 62) were recruited through the University
and community advertisements. Participants were aged 18–49
years, and reported past year gambling involvement and at least
5 lifetime gambling experiences. Exclusion criteria (confirmed
through telephone interview): a score = 8 (indicative of probable
pathological gambling) on the Problem Gambling Severity Index
(Ferris and Wynne, 2001), significant neurological or physical ill-
ness, current or past mental health problems, including substance
use and heavy smoking (>10 cigarettes/day). The study was
approved by the Cambridgeshire 4 Research Ethics Committee
(10/H0305/79). All participants gave written informed consent
and were paid £35 for their participation (plus a task-related
bonus of £6).
STUDY DESIGN
The study was a double-blind, parallel-groups, placebo-
controlled design, involving a single session at a clinical research
facility. Subjects were randomly allocated to the three treat-
ment groups: 2mg haloperidol, 50mg naltrexone or placebo
(microcritalline cellulose) hidden in identical gelatine capsules.
Upon arrival, a urine sample was taken to confirm absence of
recent opiate use, and participants completed trait question-
naires assessing impulsivity (UPPS-P; Cyders et al., 2007) and
susceptibility to gambling biases (Gambling Related Cognition
Scale; Raylu and Oei, 2004). Participants also completed the elec-
tronic Mini International Neuropsychiatric Interview (eMINI)
(Sheehan et al., 1998) for further investigation of current and
lifetime psychiatric disorders. Mental health problems were
detected in 17 participants; 7 subjects in the placebo group (alco-
hol dependence n = 4, obsessive-compulsive disorder n = 1,
hypomanic episode n = 1, bulimia nervosa n = 1), 7 subjects
in the haloperidol group (alcohol dependence n = 1, alcohol
abuse n = 2, obsessive-compulsive disorder n = 2, cocaine abuse
n = 1, generalized anxiety disorder n = 1); and 3 subjects in
the naltrexone group (alcohol dependence n = 1, hypomanic
episode n = 1, major depressive episode n = 1). The proportion
of participants meeting eMINI diagnoses did not differ across
the three treatment groups (χ2 = 2.77, p = 0.25). Given that
participants had disclosed no past or current mental health
problems in the telephone interviews, we cannot rule out the
possibility that the eMINI detections were false positives.
Following dosing, participants rested for 2.5 h to allow drug
absorption. This timing was based upon pharmacokinetic data
showing that haloperidol reaches maximal plasma concentrations
after 3 h (plasma half-life: 24 h) (Darby et al., 1995), whereas
naltrexone reaches maximal plasma concentration after 45min
with a plasma half-life of 4 h (Crabtree, 1984; Meyer et al., 1984).
After this rest period, volunteers completed the Slot Machine Task
(Clark et al., 2009) with concurrent psychophysiological moni-
toring of HR and EDA, followed by the Roulette Task (Ayton and
Fischer, 2004). Blood samples were taken pre-dosing (T1) and at
the start of the testing period (T2, +2.5 h) to measure serum pro-
lactin levels as a marker of dopaminergic tone (Ben-Jonathan and
Hnasko, 2001). Blood pressure (BP) and HR were measured with
a wrist cuff, and mood was measured with Visual Analogue Scales
(Bond and Lader, 1974), at T1, T2, and on completion of testing
(T3, +4 h). VAS data were unavailable for a single subject.
PROLACTIN ANALYSIS
Blood samples (4.7ml) were centrifuged at 4000 rpm for 5min
at room temperature to obtain serum and then distributed into
two aliquots of about 1.5ml. The samples were frozen at −80◦C
until analysis. Prolactin levels were analyzed by the National
Institute for Health Research Cambridge Biomedical Research
Center Core Biochemistry Assay Laboratory, Addenbrooke’s hos-
pital, and were tested with immunofluorometric assay (ADVIA
Centaur prolactin assay, Siemens). Results are reported in mU/L.
Prolactin samples were unavailable or contaminated by macro-
prolactin in two subjects.
TASKS
Slot machine task
Participants completed 60 trials (following 4 practice trials) on a
simplified two-reel slot machine task, described in detail in Clark
et al. (2009) (see Figure 1). Psychophysiological signals (EDA
and HR) were monitored during the task using a Biopac MP36
(see below). The screen background color (white or black) des-
ignated two choice conditions: either participant-chosen trials,
in which the participant selected the “play icon” on the left reel
by scrolling the reel up or down, and computer-chosen trials,
FIGURE 1 | The slot machine task displayed two reels, with the same
six icons on each reel. Each trial involved a fixed £0.15 p wager. After a
selection phase in which either the computer or the participant chose one
of the icons on the left reel as the “play icon,” the right reel spun for a
variable anticipation phase. The right reel decelerated and came to a
standstill. If the right reel stopped on the chosen play icon, i.e., the reels
were aligned on the central payline, the subject won £1. If the right reel
stopped on a different icon (5/6 trials), the participant lost their wager. In the
analysis of these non-wins, we distinguished near-misses (with the play
icon either side of the payline) and full-misses (with the play icon more than
one position from the payline).
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in which the play icon was selected automatically. Following
icon selection, the right reel spun and decelerated (mean spin
time: 4.2 s) to deliver a win (£1), near-miss, or full-miss out-
come (outcome duration 6 s). Current earnings were displayed
in the inter-trial interval (duration 5 s), with an initial endow-
ment of £5. The outcomes and choice condition (participant-
chosen, computer-chosen) occurred in a fixed pseudo-random
sequence such that wins occurred on 1/6, and near-misses on
1/3 trials. As a consequence of the fixed sequence, all partic-
ipants completed the task with £6, which they received as a
bonus.
On each trial, three Likert ratings were taken: following icon
selection, “How do you rate your chances of winning?” (0
to +100), and following the outcome, “How pleased are you with
the result?” (−100 to +100) and “How much do you want to
continue to play?” (0 to +100).
Roulette task
This binary choice task was modified from Ayton and Fischer
(2004). The roulette wheel displayed an equal number of red and
blue segments (see Figure 2), and on each trial, the participant
first guessed red or blue, and then gave a confidence rating on 21-
point scale. A history bar during the color choice presented the 10
previous outcomes, to minimize working memory demands that
may be independently affected by the drug treatments.
Following the color choice and confidence rating, the wheel
spun for 800–1200ms, and the outcome was presented (e.g.,
“Blue: you win”). Participants received £0.10 for correct guesses,
with no reinforcement (i.e., losses) for incorrect guesses.
Participants completed 3 practice trials, followed by a total of
90 trials, using a pre-specified color sequence in order to deliver
runs of 1–5 consecutive outcomes of the same color. This fixed
sequence had an equal probability of either color, and a prob-
ability of alternation of 0.48 (see Oskarsson et al., 2009 for
derivation). We refer to consecutive outcomes of the same color
as “outcome runs” (i.e., blue, red, red, red is an outcome run
of length 3), and consecutive correct or incorrect predictions as
“feedback streaks.” Two dependent variables were derived: (1) the
probability of choosing either color as a function of the outcome
run of that color, indicative of the Gambler’s Fallacy, (2) the con-
fidence rating as a function of feedback streak, indicative of the
Hot Hand Beliefs.
PSYCHOPHYSIOLOGICAL MEASUREMENT
During the slot machine task, electrodermal activity (EDA) and
HR calculated from electrocardiogram (ECG) were recorded via a
BIOPACMP36 unit (BIOPAC Systems Ltd, Goleta, CA, USA), fol-
lowing methods previously (Clark et al., 2012a,b). The BIOPAC
unit, sampling at 1000Hz, was connected to the stimulus deliv-
ery computer and to a second recording computer running
AcqKnowledge 4.1 software. Task events were marked on the
psychophysiological trace via a parallel port connection. EDA
was recorded through fingertip electrodes attached to the index
and middle fingers of the non-dominant hand. Heart rate was
recorded using ECG electrode patches applied to the right wrist
and left ankle. The psychophysiological data were extracted using
in-house scripts developed inMicrosoft Visual Basic (v6.0): activ-
ity on the slot machine task was modeled to the time of outcome
delivery, using change from baseline scores calculated from the
mean activity in the final 2 s of reel spin. Mean EDA was extracted
in 6 × 2 s bins from the onset of the outcome phase. An EDA sum-
mary measure was calculated from the maximum change from
baseline value in bins 2–4 (i.e., 2–8 s post-outcome), given the
typical time-course for EDA changes (Dawson et al., 2000). HR
responses were calculated using the median HR in 12 × 0.5 s bins
from the onset of the outcome phase. TwoHR summarymeasures
isolated the initial HR deceleration component (the minimum
value in bins 1–6, i.e., 0–3 s post-outcome, minus the baseline)
and the subsequent HR acceleration component (the maximum
in bins 7–12, i.e., 3–6 s post-outcome, minus the deceleration
minima) (Hodes et al., 1985; Bradley, 2000).
STATISTICAL ANALYSIS
Statistical analysis was performed in SPSS version 19.0.
Demographic and trait variables were compared across groups
using One-Way ANOVA. Fisher’s least significant difference test
was used for post-hoc comparisons, as is appropriate for 3-group
designs (Cardinal and Aitken, 2006). Mood scales, cardiovascular
FIGURE 2 | The roulette task presented a color choice (red or
blue) on each trial, followed by a confidence rating. The
roulette wheel then spun, and the outcome and feedback were
presented. A history bar across the top of the screen indicated
the last ten outcomes, to alleviate any working memory
requirements.
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measures, and prolactin levels were assessed with mixed-model
ANOVAs including Timepoint as a within-subjects factor.
On the slot machine task, the subjective ratings and psy-
chophysiology summary measures were analyzed with mixed-
model ANOVA, with Outcome (wins, near-misses, full-misses)
and Choice (participant-chosen, computer-chosen) as within-
subjects factors, and Treatment (3 levels: haloperidol, naltrexone,
placebo) as a between-subjects factors. Data from the roulette task
were analyzed using two mixed-model ANOVAs, with Treatment
(3 levels: placebo, haloperidol, naltrexone) as the between-
subjects factor. For analysis of color predictions, Outcome Run
length was the within-subjects factor. For the analysis of confi-
dence ratings, Feedback Streak length and Outcome (winning,
losing) were within-subjects factors. Simple main effects analysis
of the roulette task data compared shorter runs/streaks (1–2 suc-
cessive events) against longer runs/streaks (4–5 successive events).
As the feedback streaks were not pre-specified, some subjects did
not experience any longer streaks. For participants missing only
streaks of length five, we imputed their streak length 4 value for
their missing value (this is a conservative approach that under-
estimates any effect of the longer streaks). Three participants
were excluded who did not experience streaks longer than three
events. In addition, one further participant was excluded who
did not vary either his color choice or confidence ratings across
the task.
As the primary aim of this study was to compare the effects
of haloperidol and naltrexone relative to the placebo condition,
rather than the direct comparison of the two active treatments,
the omnibus 3-group model was decomposed using two planned
comparisons of the haloperidol group vs. placebo, and the nal-
trexone group vs. placebo. For all analyses, the Greenhouse-
Geisser correction was applied when sphericity assumptions were
violated, and the Huynh-Feldt correction was reported when the
Greenhouse-Geisser estimate was greater than 0.75 (Cardinal and
Aitken, 2006). All tests were thresholded at p < 0.05 two-tailed.
RESULTS
The three treatment groups did not differ significantly in age,
years of education, trait gambling distortions, or impulsivity (see
Table 1). The overall level of problem gambling was low on the
PGSI (mean 1.5; SD 1.73; range 0–7; a score = 8 is indicative of
probable pathological gambling), but GRCS scores were in range
Table 1 | Participant characteristics and demographic details.
Placebo Haloperidol Naltrexone Test statistic
(N = 20) (N = 21) (N = 21)
Age (years) 27.2 (8.0) 26.6 (7.1) 27.1 (8.3) F(2, 61) = 0.04, NS
Education 17.4 (3.1) 16.3 (3.1) 16.7 (2.3) F(2, 61) = 0.68, NS
PGSI 1.6 (1.7) 1.6 (1.8) 1.3 (1.8) F(2, 61) = 0.17, NS
GRCS 47.7 (21.2) 53.4 (15.1) 58.0 (18.1) F(2, 61) = 1.64, NS
UPPS-P 137.8 (17.8) 128.3 (23.4) 129.2 (14.6) F(2, 61) = 1.57, NS
The values are reported in means and standard deviations; PGSI, problem
gambling severity index (range 0–27); GRCS, gambling-related cognitions scale
(range 23–161), UPPS-P Impulsivity Scale (range 59–236). NS, not significant.
of previous data in recreational gamblers (Raylu and Oei, 2004;
Billieux et al., 2012).
PROLACTIN LEVELS
For plasma prolactin levels, there was a significant Treatment ×
Time interaction [F(2, 57) = 4.09, p = 0.022, η2p = 0.13]. The
main effects of Treatment [F(2, 57) = 2.42, p = 0.098, η2p = 0.08]
and Time [F(1, 57) = 3.44, p = 0.069, η2p = 0.06] approached
significance. Analysis of change scores (T2minus T1) indi-
cated prolactin increase in the naltrexone group compared to
placebo [t(38) = −2.78, p = 0.008], consistent with downstream
dopaminergic blockade by naltrexone. The haloperidol group did
not differ significantly from placebo (p > 0.1) (see Figure 3).
MOOD AND CARDIOVASCULAR MEASURES
On the subjective mood ratings, there were no differences
between treatment groups (i.e., the Treatment× Time interaction
term) for Alertness [F(4, 116) = 1.06, NS], Happiness [F(4, 116) =
1.70, NS] or Calmness [F(4, 116) = 0.09, NS].Main effects of Time
were observed on Alertness [F(2, 116) = 23.10, p < 0.001, η2p =
0.29] and Happiness [F(2, 116) = 7.26, p = 0.001, η2p = 0.11],
reflecting a general decrease over time across all groups.
On the cardiovascular measures, there were no differences
between treatment groups (i.e., Treatment × Time interac-
tions) on HR [F(4, 116) = 1.07, NS], systolic BP [F(3.3, 96.2) =
1.76, NS] or diastolic BP [F(4, 116) = 1.65, NS]. Systolic BP
and HR decreased over time across all groups [main effect of
Time: F(1.7, 96.2) = 3.92, p < 0.030, η2p = 0.06; F(2, 116) = 45.49,
p < 0.001, η2p = 0.44, respectively].
SLOT MACHINE TASK
Subjective effects of wins and near-misses
On the ratings of “pleased with outcome,” the omnibus ANOVA
revealed a significant main effect of Outcome [F(1.0, 59.0) =
189.66, p < 0.001, η2p = 0.77], such that participants were more
pleased after wins compared to near-misses [t(59) = 13.15, p <
0.001] and full-misses [t(59) = 13.40, p < 0.001] (see Table 2).
Near misses were more pleasant than full misses [t(59) = 2.19,
FIGURE 3 | Prolactin levels (mU/L) at T1 (baseline) and T2 (start of
testing period). Naltrexone significantly increased prolactin levels. Error
bars indicate standard errors of the means.
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p = 0.033]. An Outcome × Choice interaction was observed
[F(1.5, 84.0) = 4.32, p = 0.026, η2p = 0.07], such that for near-
misses and full-misses, participant-chosen outcomes were signif-
icantly less pleasant than computer-selected outcomes [t(59) =
2.32, p = 0.024; t(59) = 2.84, p = 0.006; respectively], whereas
for wins, pleasantness ratings did not differ by choice condition
[t(59) = 1.46, p = 0.149]. An Outcome × Treatment interaction
was observed [F(2.1, 59.0) = 4.15, p = 0.020, η2p = 0.13], driven
by an effect of haloperidol [haloperidol model: F(1.0, 39.1) =
6.56, p = 0.014, η2p = 0.15; naltrexone model: F(1.0, 38.6) = 0.85,
NS]. The haloperidol group rated higher pleasure after wins
[t(38) = −2.20, p = 0.034] and greater unpleasantness after non-
wins [near-misses: t(38) = 2.16, p = 0.038; full-misses: t35.7 =
2.36, p = 0.024] compared to the placebo group (see Table 2).
Thus, on a subjective rating, haloperidol appeared to potenti-
ate both the positive affect to winning as well as negative affect
following non-winning outcomes.
On the rating of “continue to play,” the omnibus ANOVA
revealed a significant main effect of Outcome [F(1.2, 67.0) = 45.5,
p < 0.001, η2p = 0.44], reflecting higher ratings after wins com-
pared to non-wins [near-misses: t(59) = 6.60, p < 0.001; full-
misses: t(59) = 7.53, p < 0.001]. There was anOutcome×Choice
interaction [F(2, 114) = 13.5, p < 0.001, η2p = 0.19]: the desire
to play was higher after participant-chosen near-misses, com-
pared to computer-chosen near-misses [t(59) = 5.00, p < 0.001],
and participant-chosen full-misses [t(59) = 4.78, p < 0.001], as
previously observed on this task (Clark et al., 2009, 2012a,b).
There was also an Outcome × Choice × Treatment interaction
[F(4, 114) = 3.39, p = 0.012, η2p = 0.11], driven by an effect of
naltrexone [F(2, 74) = 3.57, p = 0.033, η2p = 0.09] [haloperidol
model: F(2, 76) = 0.42, NS]. In the placebo group, the participant-
chosen near-misses were rated as more motivating than
Table 2 | Subjective ratings on the slot machine task.
Placebo Haloperidol Naltrexone
“CHANCES OF WINNING?”
Participant 38.8 (19.2) 46.0 (17.9) 40.9 (16.8)
Computer 32.7 (16.7) 36.7 (15.2) 36.5 (15.2)
“PLEASED WITH RESULT?”
Win, participant 32.0 (31.3) 56.6 (30.7) 49.9 (27.1)
Win, computer 34.1 (26.3) 51.2 (35.5) 43.4 (25.8)
Near-miss, participant −28.8 (21.2) −49.9 (27.7) −28.4 (19.7)
Near-miss, computer −29.2 (23.9) −42.9 (28.4) −24.9 (17.6)
Full-miss, participant −27.8 (20.1) −47.2 (28.7) −26.1 (18.9)
Full-miss, computer −26.4 (19.3) −42.6 (27.9) −21.8 (16.6)
“CONTINUE TO PLAY?”
Win, participant 51.8 (24.6) 60.1 (23.1) 62.3 (13.5)
Win, computer 52.2 (24.4) 62.5 (20.6) 59.2 (12.7)
Near-miss, participant 45.2 (21.3) 56.3 (19.8) 53.6 (12.1)
Near-miss, computer 40.5 (24.7) 51.4 (21.3) 52.2 (11.1)
Full-miss, participant 42.2 (23.1) 51.1 (22.9) 52.3 (12.0)
Full-miss, computer 44.3 (21.9) 53.3 (21.4) 53.5 (11.4)
Values are reported as mean (SD), separated by the participant-chosen condition
and the computer-chosen condition.
either computer-chosen near-misses [t(18) = 3.27, p < 0.001] or
participant-chosen full-misses [t(18) = 3.66, p < 0.001]. These
differences were not observed in the naltrexone group (all ps >
0.1) and the calculated difference score between participant-
chosen and computer-chosen near-misses was marginally higher
in the placebo group than in the naltrexone group [t(37) = 1.80,
p = 0.08]. Thus, naltrexone had amodest effect of attenuating the
motivational ratings after self-selected near-misses (see Figure 4).
Psychophysiological responses to wins and near-misses
For EDA max, there were significant main effects of Outcome
[F(1.4, 77.4) = 24.8, p < 0.001, η2p = 0.31] and Choice [F(1, 56) =
28.0, p < 0.001, η2p = 0.33]. Across all groups, participants expe-
rienced higher EDA responses after wins compared to non-wins
[near-misses: t(58) = 5.42, p < 0.001; full-misses: t(58) = 5.14,
p < 0.001]. There was a marginal increase in EDA after near-
misses in comparison to full-misses [t(58) = 1.98, p = 0.053].
Participants showed higher EDA on participant-chosen outcomes
compared to computer-chosen outcomes [wins: t(58) = 2.06, p =
0.044; near-misses: t(58) = 4.32, p < 0.001; full-misses: t(58) =
2.72, p = 0.009]. There was a significant Outcome × Treatment
interaction [F(2.8, 77.4) = 3.52, p = 0.022, η2p = 0.11], which was
driven by the naltrexone group [F(1.4, 51.9) = 5.09, p = 0.018,
η2p = 0.12] [haloperidol model: F(1.3, 46.0) = 0.15, NS]. The EDA
change to wins relative to full-misses was greater in the naltrexone
group than the placebo group [t(37) = −2.47, p = 0.018], as well
as marginally higher for the near-miss vs. full-miss change score
[t(37) = −1.80, p = 0.081] (see Figure 5A). Thus, naltrexone
increased the physiological responsiveness to wins in comparison
to full-misses (Table 3).
FIGURE 4 | Motivational ratings on the slot machine task showed an
outcome (near-miss, full-miss) by control (participant-chosen,
computer-chosen) interaction, whereby participant-chosen
near-misses increased motivation to continue relative to the
computer-chosen near-misses, in the placebo group (and haloperidol
group), and this was attenuated in the naltrexone group. Error bars
indicate standard error of the mean. ∗p < 0.08.
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FIGURE 5 | Psychophysiological responses on the slot machine task: (A)
Naltrexone significantly increased post-outcome EDA following wins
compared to both non-win outcomes (collapsing across choice
conditions). (B) The naltrexone group displayed marginally elevated
post-outcomeHRdeceleration followingwinscompared tonon-wins (collapsing
across choice conditions). Error bars indicate standard error of the mean.
Table 3 | Psychophysiological responses to outcomes on the slot
machine task (change scores from baseline).
Placebo Haloperidol Naltrexone
EDA MAX
Win, participant 0.30 (0.23) 0.20 (0.17) 0.42 (0.42)
Win, computer 0.23 (0.22) 0.18 (0.21) 0.36 (0.44)
Near-miss, participant 0.22 (0.19) 0.13 (0.14) 0.25 (0.30)
Near-miss, computer 0.15 (0.18) 0.07 (0.12) 0.17 (0.30)
Full-miss, participant 0.21 (0.17) 0.10 (0.11) 0.16 (0.21)
Full-miss, computer 0.16 (0.13) 0.7 (0.10) 0.11 (0.15)
HR DECELERATION
Win, participant −2.4 (1.8) −3.6 (2.2) −4.7 (3.0)
Win, computer −3.4 (2.9) −3.4 (2.0) −4.4 (4.7)
Near-miss, participant −3.0 (1.9) −3.6 (1.6) −3.9 (2.6)
Near-miss, computer −2.8 (2.0) −3.7 (1.4) −3.8 (3.6)
Full-miss, participant −2.7 (1.4) −2.9 (1.0) −3.2 (2.1)
Full-miss, computer −3.0 (2.0) −2.8 (1.3) −3.3 (2.5)
HR ACCELERATION
Win, participant 5.8 (3.6) 6.1 (3.2) 7.3 (4.8)
Win, computer 5.0 (2.9) 5.6 (3.4) 6.2 (5.2)
Near-miss, participant 6.1 (2.7) 6.5 (2.9) 7.1 (5.1)
Near-miss, computer 5.8 (2.3) 6.9 (3.5) 7.5 (5.4)
Full-miss, participant 5.7 (2.4) 6.1 (3.3) 6.4 (5.0)
Full-miss, computer 4.9 (1.8) 5.3 (2.5) 5.7 (4.1)
Values are reported as mean (SD), separated by participant-chosen condition
and the computer-chosen condition. EDA, electrodermal activity, in µS, where
the Max refers to the maximum value across bin 2–4 (i.e., 2–8 s post-outcome)
minus the pre-trial baseline. HR, heart rate, in beats per minute, where the
Deceleration value refers to the minimum value in bins 1–6 (i.e., 0–3 s post-
outcome) minus the baseline; and the subsequent HR acceleration component
refers to the maximum in bins 7–12 (i.e., 3–6 s post-outcome) minus the
deceleration minima.
On HR deceleration, there was a main effect of Outcome
[F(2, 106) = 6.44, p = 0.002, η2p = 0.11], with greater HR decel-
erations after wins and near-misses in comparison to full-
misses [t(55) = −3.23, p = 0.002; t(55) = −3.03, p = 0.004;
respectively]. A trend Outcome × Treatment interaction was
observed [F(4, 106) = 2.11, p = 0.085, η2p = 0.074], driven by
an effect of naltrexone [F(2, 70) = 2.86, p = 0.064, η2p = 0.08]
[haloperidol model: F(2, 68) = 1.64, NS]. The HR deceleration to
wins relative to full-misses was greater in the naltrexone group
than the placebo group [t(35) = 2.17, p = 0.03] (see Figure 5B),
similar to the EDA effect. For HR acceleration, there was a sig-
nificant effect of Outcome [F(1.8, 93.4) = 8.12, p = 0.001, η2p =
0.13], reflecting higher HR acceleration after near-misses relative
to wins [t(55) = 2.45, p = 0.018] and full-misses [t(55) = 4.99,
p < 0.001]. There was also a main effect of Choice [F(1, 53) =
4.17, p = 0.046, η2p = 0.07], indicating higher HR acceleration
for participant-chosen outcomes compared to computer-chosen
outcomes [wins: t(55) = 2.02, p = 0.048; full-misses: t(55) = 2.89,
p = 0.006]. The HR acceleration effects did not interact with
Treatment group.
Subjective effects of personal choice (the illusion of control)
On the ratings of “chances of winning,” participants reported a
greater expectancy of winning when they chose the play icon,
compared to the computer-chosen condition [F(1, 57) = 44.59,
p < 0.001, η2p = 0.44]. This effect did not vary across treatment
groups [Treatment × Choice: F(2, 57) = 2.19, NS; Treatment:
F(2, 57) = 0.59, NS] (see Table 2).
ROULETTE TASK
Gambler’s fallacy
The analysis of color choice yielded a main effect of Run Length
[F(1, 55) = 7.84, p = 0.007, η2p = 0.13], reflecting decreased
choice of choosing either color after a longer run of that color
(M = 43.1, SD = 23.6) compared to a short run (M = 50.9,
SD = 9.5). This represents a typical Gambler’s fallacy pattern.
Treatment group did not moderate this effect [Run Length ×
Treatment: F(2, 55) = 1.07, NS; Treatment: F(2, 55) = 0.74, NS].
Hot hand belief
Analysis of confidence ratings as a function of feedback streak
showed a weak effect of Outcome [F(1, 55) = 3.34, p = 0.073,
η2p = 0.06], whereby confidence was higher after correct predic-
tions compared to incorrect predictions, in line with the hot hand
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belief. The Streak Length × Outcome × Treatment interaction
approached significance [F(2, 55) = 2.51, p = 0.091, η2p = 0.08].
This effect was driven by the naltrexone group, in which a sig-
nificant 3-way interaction [F(1, 35) = 5.41, p = 0.026, η2p = 0.13]
and a trend Outcome × Treatment interaction [F(1, 35) =
3.81, p = 0.059, η2p = 0.10] were observed [haloperidol model:
F(1, 37) = 2.37, NS]. Analysing winning and losing streaks sepa-
rately in the naltrexone model, the Streak Length × Treatment
interaction approached significance for wins [F(1, 35) = 3.43, p =
0.073, η2p = 0.09], but not for losses [F(1, 35) = 1.91, NS], such
that the naltrexone group showed a greater increase in confidence
on longer winning streaks, compared to placebo (see Figure 6).
DISCUSSION
In this study, we assessed the effects of the opioid antagonist nal-
trexone and the dopamine D2-receptor antagonist haloperidol on
two gambling tasks in male recreational gamblers. A slot machine
task was used to deliver near-miss outcomes, elicit perceptions of
control, and to measure physiological responses to winning out-
comes. A roulette task was used to study the impact of outcome
runs and feedback streaks on choice behavior and confidence rat-
ings, respectively. Collapsing across the three treatment groups,
both tasks were reasonably successful at inducing these gambling
phenomena. On the slot machine task, the jackpot wins were
rated as pleasurable and increased the motivation to play, and
the winning outcomes were also associated with increased EDA
and HR deceleration, relative to the non-wins. Comparing near-
misses to full-misses, we confirmed our previous results on this
task, that motivation ratings were higher after near-misses, and
this effect depended on personal choice over the gamble (Clark
et al., 2009, 2012a). The perceived chances of winning were also
higher on participant-chosen trials than computer-chosen trials,
consistent with an illusion of control. Near-misses were associ-
ated with increased EDA and reboundHR acceleration, as we have
FIGURE 6 | Confidence ratings on the roulette task as a function of
winning streak length show a marginal difference between the
naltrexone and placebo groups. Error bars indicate standard error of the
mean.
described previously (Clark et al., 2012a, 2013). On the roulette
task, there was an expected Gambler’s Fallacy effect, such that the
choice of either color decreased after long runs of that color (i.e.,
negative recency) (replicating Ayton and Fischer, 2004). There
was also a weaker effect of increased confidence after wins com-
pared to losses, consistent with the “Hot Hand” belief (Ayton and
Fischer, 2004).
In terms of the pharmacological effects, several differences
were observed between the treatment groups, although generally,
these were not in line with our predictions. The three groups
were demographically matched and did not differ significantly
on impulsivity, a relevant personality trait, or level of gam-
bling involvement (PGSI) or trait gambling cognitions (GRCS).
Prolactin levels increased in the naltrexone-treated group, but did
not differ significantly between the haloperidol group and the
placebo group. This implies that the single low dose of naltrex-
one (50mg) was functionally active, but that the 2mg haloperidol
dose may not have been. Indeed, on the two gambling tasks,
the majority of the detected group differences were between
the naltrexone and placebo groups: the naltrexone group had a
greater physiological response to winning outcomes on the slot
machine task, in terms of EDA (significant) and HR decelera-
tion (marginally significant). On the roulette task, the naltrexone
group showed marginally higher confidence ratings after win-
ning streaks compared to the placebo group, indicating a possible
enhancement of the hot hand effect. At the same time, the moti-
vational effect of the near-misses on participant-chosen trials
was significantly attenuated in the naltrexone group. By con-
trast, in the haloperidol group, the only observed effect was a
greater disparity in pleasantness ratings between the win and non-
win outcomes (i.e., a treatment by outcome interaction). Neither
group showed differences in the effect of personal control on the
slot machine task, or the Gambler’s Fallacy on the roulette task.
EFFECTS OF NALTREXONE ON GAMBLING BEHAVIOR
Based upon the reported clinical efficacy of naltrexone in the
treatment of pathological gambling (Kim et al., 2001; Grant
et al., 2006, 2008), our overarching hypothesis for the naltrex-
one group was that cognitive effects characteristic of excessive
gambling would be ameliorated by naltrexone. In addition, we
predicted that these participants would show blunted responses
to wins (c.f. Petrovic et al., 2008). Our data indicated that nal-
trexone did modulate the responsivity to wins, but in the opposite
direction to that predicted: the naltrexone group displayed higher
EDA following wins, and this hyper-reactivity was substantiated
by a trend effect for HR deceleration. Prima facie, these results
are difficult to reconcile with the substantial literature report-
ing that opioid blockade reduces reward processing in laboratory
models (Drewnowski et al., 1995; Zhu et al., 2011; Langleben
et al., 2012a), and reduces cravings and drug self-administration
in groups with substance use disorders (Davidson et al., 1999;
Drobes et al., 2004; Myrick et al., 2008; Langleben et al., 2012b;
Miranda et al., 2013).
A number of methodological differences may be pertinent
here, and may be useful to inform the design of future experi-
ments. A key point is that our participants were recreational gam-
blers with modest levels of gambling involvement; it is possible
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that pathological gamblers may show a qualitatively different
response to opioid blockade. Our decision to use recreational
gamblers was based on several factors: the ease of recruitment
to achieve sufficient group sizes, ethical considerations about
the use of gambling simulations in individuals with disordered
gambling, and evidence that gambling severity is dimensional
(Toce-Gerstein et al., 2003). However, within the context of sub-
stance addictions (namely alcohol dependence), the response to
naltrexone is known to vary as a function of genetics (the OPRM1
polymorphism) (Ray and Hutchison, 2007) and family history of
alcoholism (Krishnan-Sarin et al., 2007). Family history of alco-
holism is also a predictor of a positive treatment response to
naltrexone in pathological gamblers (Grant et al., 2008). In the
study by Krishnan-Sarin et al. (2007), while naltrexone acted to
decrease drinks consumed in a laboratory test in heavy drinkers
with a family history of alcoholism, naltrexone actually increased
drinking in those who were family history negative, similar to the
effects observed here. The authors speculated that this effect may
have been linked to individual difference in kappa-opioid action,
which increase alcohol consumption in a rodent model (Mitchell
et al., 2005).
In the most comparable study to the present experiment,
Petrovic et al. (2008) found reduced brain responses to win-
ning outcomes following opioid blockade in healthy participants,
coupled with greater activation to monetary losses. However,
the Petrovic et al. (2008) study (and also Drewnowski et al.,
1995) used naloxone rather than naltrexone, and delivered intra-
venously rather than orally. The more rapid changes in brain con-
centrations associated with intravenous injection as opposed to
oral dosing may cause divergent effects on behavior, as in the case
of methylphenidate (Volkow and Swanson, 2003). Naltrexone
may also exert partial agonism effects (Ignar et al., 2011), and
along with naloxone and nalmefene, it is onlymoderately selective
for the μ-opioid receptor, which may modify its effects on reward
seeking behavior (Giuliano et al., 2012). As a third notable differ-
ence, the majority of past work in clinical groups has employed
either subchronic (e.g. 7 day) dosing (e.g., Davidson et al., 1999;
Drobes et al., 2004; Myrick et al., 2008) or slow-release depot for-
mulations (Langleben et al., 2012a). Compensatory effects can
occur in single-dose designs; for example, single dose citalopram
treatment in healthy volunteers induced an impairment in rever-
sal learning that was comparable to (rather than opposite to)
effects observed in patients with major depression (Chamberlain
et al., 2006). Nevertheless, the single administration of naltrexone
used in the present study was seen to increase plasma pro-
lactin levels, replicating Shaw and Al’Absi (2010). Given that
prolactin release is inhibited by hypothalamic dopamine trans-
mission (Freeman et al., 2000), a prolactin rise is presumed
to reflect downstream dopamine blockade, indicative of overall
opioid down-regulation.
In terms of the other gambling distortions under study, our
findings were mixed. Consistent with the increased responsivity
to wins, there was also an indication of enhanced confidence after
winning streaks (i.e., increased “hot hand” effect). However, the
motivational effects of near-miss outcomes were blunted in the
naltrexone group. Given that the naltrexone effect on near-misses
was restricted to a subjective rating (“continue to play”) and did
not generalize to the psychophysiological measures, this result
should be treated with caution. Moreover, the naltrexone group
did not differ from placebo on two cardinal gambling distortions,
the Gambler’s Fallacy (on the roulette task) and the illusion of
control (the manipulation of personal choice on the slot machine
task), despite the fact that these distortions were robustly elicited
in the overall study group. Related to the possibility that patho-
logical gamblers may show a distinctive response to naltrexone,
it is also conceivable that pathological and recreational gamblers
may differ in their responses to gambling effects like near-misses
(Habib and Dixon, 2010) or illusory control (Orgaz et al., 2013).
EFFECTS OF HALOPERIDOL ON GAMBLING BEHAVIOR
Prior research has shown that the stimulation of dopamine trans-
mission can induce (Voon et al., 2009) and exacerbate (Zack and
Poulos, 2004) gambling tendencies, as well as specific distortions
including the sense of agency (relevant to the illusion of control)
(Moore et al., 2010) and the behavioral response to near-misses
(Winstanley et al., 2011). There is some evidence that these effects
are D2-receptor specific (Zack and Poulos, 2007; Weintraub et al.,
2010; Winstanley et al., 2011). Based on the argument by Frank
and O’Reilly (2006) that lower doses of dopamine D2 receptor
antagonists act preferentially on presynaptic D2 auto-receptors to
increase dopamine transmission (see also Zack and Poulos, 2007),
we predicted that low dose haloperidol would enhance the reac-
tivity to win and near-miss outcomes on the slot machine task,
and increase the influence of personal choice. We found lim-
ited support for these predictions, and haloperidol showed few
effects in this study. The only statistically significant difference
from the placebo group was on the pleasantness ratings on the
slot machine task, where the haloperidol group showed increased
pleasantness ratings after wins and increased ratings of unpleas-
antness after non-win outcomes. This effect was not corroborated
by any change in physiological reactivity under haloperidol. It
should also be noted that collapsing across treatment groups, the
pleasantness ratings varied significantly as a function of personal
choice (i.e., an Outcome × Choice interaction), but no 3-way
interaction was evident with treatment group. We infer that the
haloperidol group may have been more extreme in their affective
ratings, but that this may not constitute a genuine drug action.
Notably, the lack of any observed effect of haloperidol on pro-
lactin levels raises the possibility that the 2mg dosage may not
have been functionally active. In the study by Frank and O’Reilly,
2mg haloperidol significantly increased prolactin levels in a cross-
over design. While we note that our post-dose plasma sample
was obtained slightly earlier (at 2.5 h) than the expected peak
(at 3 h in Darby et al., 1995; at 4 h in Frank and O’Reilly, 2006),
we also observed no cardiovascular or mood effects, unlike past
reports (Zack and Poulos, 2007; Pine et al., 2010). A number of
other studies have employed low doses of haloperidol (1–3mg)
in 3-arm studies that have included a group treated with the
dopamine precursor levodopa (Pessiglione et al., 2006; Pleger
et al., 2009; Pine et al., 2010; Oei et al., 2012). These studies have
generally succeeded in demonstrating linear effects (i.e., haloperi-
dol < placebo < levodopa) on reinforcement-related parameters,
although in several instances, the specific haloperidol vs. placebo
contrast was either non-significant (Pine et al., 2010), or not
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reported (Pessiglione et al., 2006; Oei et al., 2012). Of course,
based upon the argument of presynaptic upregulation, an inter-
mediate dose may exist where the presynaptic and post-synaptic
actions cancel each other out. It is also recognized that both pha-
sic and tonic components of dopamine signaling are implicated
in reward-driven behavior, and that a presynaptic manipulation
may primarily affect phasic firing (Grace, 1991; Niv et al., 2007).
Overall, we find limited evidence for functional effects of the 2mg
dose, and the absence of a significant prolactin response is partic-
ularly concerning; we recommend that future studies in healthy
participants opt for higher doses ≥3mg.
LIMITATIONS AND CONCLUSION
This study was the first to assess the effects of an opioid
antagonist, naltrexone, and a dopamine D2-receptor antagonist,
haloperidol, on gambling tendencies. The indications of increased
gambling proclivity following naltrexone (increased physiologi-
cal reactivity to wins, increasing confidence ratings on winning
streaks) are at odds with the reported clinical efficacy of naltrex-
one in pathological gambling, although the non-clinical study
population and single dose administration design necessarily
limit any direct comparison. As a strength of the study, the
two tasks were successful at inducing the key cognitive distor-
tions of interest in the overall study group. While the group
comparisons involved no correction for the multiple dependent
variables (hence risk of Type I error), we sought to corrobo-
rate effects on behavioral measures and subjective ratings with
the acquisition of event-related psychophysiology, which success-
fully demonstrated significant EDA and HR reactivity to wins
and near-misses. We opted to use a 3-arm, parallel-groups design,
because our tasks were not known to be suitable for repeated test-
ing, although this decision had several consequences. First, the
direct comparisons involved non-independent tests against the
same placebo group, and some of the specific gambling effects
(HR deceleration to wins, the hot hand effect) were not selec-
tively evident in the placebo group. In addition, between-groups
analysis limits any examination of individual differences in drug
responses; for example whether dopamine or opioid effects var-
ied with age or trait impulsivity (Zack and Poulos, 2009). As
further limitations, we acknowledge that laboratory-based gam-
bling simulations entail some compromises to ecological validity
(Gainsbury and Blaszczynski, 2011). While our slot machine task
delivered real monetary wins, which is important for establish-
ing physiological arousal (Ladouceur et al., 2003), our tasks did
not involve a variable wager. With regard to the limited effects
of haloperidol on the gambling tasks, we highlight the non-
significant change in prolactin as an indication that our low dose
may not have achieved functional effectiveness, and as such, the
null effects for haloperidol on the gambling tasks may say lit-
tle about the relevance of dopamine signaling pathways to the
neurobiology of gambling or the treatment potential of dopamin-
ergic medications. However, the observed actions of naltrex-
one substantiate the relevance of opioid transmission to human
decision-making and reinforcement processing, with treatment
implications for a range of addictive and impulse control- related
disorders.
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